LABT

Aug 31, 4:30 PMU.S. patent allowance for antimicrobial compounds drives 40% LABT after-hours surge

Peers: COAG VBIO AARD ABVC ABOS ABEO ACET ABVX ABCL SRXH

Index	-
Market Cap	7.10M
Enterprise Value	2.62M
Income	-7.35M
Sales	0.00M
Book/sh	2.00
Cash/sh	1.93
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	5
IPO	Apr 23, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.50
P/C	1.55
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.70
Current Ratio	7.70
Debt/Eq	0.02
LT Debt/Eq	0.00
Option/Short	No / No

EPS (ttm)	-10.34
EPS next Y	-
EPS next Q	-2.66
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	17.02% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-140.44%
Sales Y/Y TTM	-
EPS Q/Q	-769.45%
Sales Q/Q	-
Earnings	Jun 03
EPS/Sales Surpr.	- -

Insider Own	33.38%
Insider Trans	0.00%
Inst Own	4.13%
Inst Trans	61.85%
ROA	-225.45%
ROE	-402.84%
ROIC	-169.64%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	28.33%
SMA50	18.92%
SMA200	-70.05%
Trades

Shs Outstand	2.17M
Shs Float	1.58M
Short Float	3.56%
Short Ratio	0.03
Short Interest	0.06M
52W High	98.20 -96.95%
52W Low	1.66 80.58%
Volatility	13.24% 10.70%
ATR (14)	0.41
RSI (14)	54.64
Beta	-
Rel Volume	5.88
Avg Volume	1.67M
Volume	492,157

Perf Week	30.90%
Perf Month	38.78%
Perf Quarter	-51.65%
Perf Half Y	-
Perf YTD	-96.25%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	12.00
Prev Close	2.50
Price	3.00
Change %	19.90%

Aug-25-26 05:36PM	Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company (NewMediaWire) +7.51% +6.99%
Jul-22-26 08:02AM	Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PR Newswire) +83.33%
Jul-15-26 08:02AM	Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel (PR Newswire)
Jul-07-26 08:02AM	Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance (PR Newswire) -12.77%
Jun-25-26 08:02AM	Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers (PR Newswire) -7.80%
08:02AM	Loading…
Jun-22-26 08:02AM	Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin Compounds Being Developed for High-Need Antimicrobial Infections (PR Newswire) -5.46%
Jun-16-26 08:02AM	Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum (PR Newswire)
May-27-26 08:02AM	Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers (PR Newswire)
May-18-26 08:02AM	Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers (PR Newswire) -36.65%
May-12-26 08:02AM	Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3 (PR Newswire)
Apr-28-26 07:33AM	Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors (PR Newswire) +6.28%
Apr-23-26 10:42AM	Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT" (PR Newswire)

Lakewood-Amedex Biotherapeutics, Inc. engages in the development of novel antimicrobial therapies. Its anti-infective products targeted certain viral diseases like avian influenza, Epstein Barr Virus (EBV), and hepatitis B and C. The company was founded by Roderic Dale on July 11, 2006 and is headquartered in Bradenton, FL.

CEODr. Kelvin Cooper Ph.D.

CFO & VP of AdministrationMr. Peter F. Ceccacci

Ph.D.Dr. Thomas Balzer M.D.

Project Manager & Accounting ManagerMs. Tara Endress

Investor RelationsDaniel Kontoh-Boateng

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Lakewood-Amedex Biotherapeutics Inc

Upgrade your Finviz experience